Selection and expansion of natural killer cells for NK cell-based immunotherapy
Natural killer (NK) cells have been used in several clinical trials as adaptive immunotherapy. The low numbers of these cells in peripheral blood mononuclear cells (PBMC) have resulted in various approaches to preferentially expand primary NK cells from PBMC. While some clinical trials have used th...
Main Authors: | Becker, Petra S. A., Suck, Garnet, Nowakowska, Paulina, Ullrich, Evelyn, Seifried, Erhard, Bader, Peter, Tonn, Torsten, Seidl, Christian |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer Berlin Heidelberg
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826432/ |
Similar Items
-
CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
by: Romanski, Annette, et al.
Published: (2016) -
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
by: Sun, Cheng, et al.
Published: (2015) -
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
by: Klingemann, Hans, et al.
Published: (2016) -
Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol
by: Koehl, Ulrike, et al.
Published: (2013) -
ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
by: Zhang, Congcong, et al.
Published: (2013)